- Home
- TNMG vs MDXH Comparison
TNMG vs MDXH Comparison
Compare TNMG & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNMG
- MDXH
- Stock Information
- Founded
- TNMG 2023
- MDXH 2003
- Country
- TNMG Japan
- MDXH Belgium
- Employees
- TNMG N/A
- MDXH N/A
- Industry
- TNMG
- MDXH
- Sector
- TNMG
- MDXH
- Exchange
- TNMG NYSE
- MDXH Nasdaq
- Market Cap
- TNMG 93.7M
- MDXH 93.1M
- IPO Year
- TNMG N/A
- MDXH 2021
- Fundamental
- Price
- TNMG $2.93
- MDXH $1.88
- Analyst Decision
- TNMG
- MDXH Strong Buy
- Analyst Count
- TNMG 0
- MDXH 2
- Target Price
- TNMG N/A
- MDXH $7.00
- AVG Volume (30 Days)
- TNMG 48.3K
- MDXH 119.5K
- Earning Date
- TNMG 01-01-0001
- MDXH 02-26-2025
- Dividend Yield
- TNMG N/A
- MDXH N/A
- EPS Growth
- TNMG N/A
- MDXH N/A
- EPS
- TNMG N/A
- MDXH N/A
- Revenue
- TNMG N/A
- MDXH $84,708,000.00
- Revenue This Year
- TNMG N/A
- MDXH $28.76
- Revenue Next Year
- TNMG N/A
- MDXH $19.91
- P/E Ratio
- TNMG N/A
- MDXH N/A
- Revenue Growth
- TNMG N/A
- MDXH 33.01
- 52 Week Low
- TNMG $1.89
- MDXH $1.55
- 52 Week High
- TNMG $34.08
- MDXH $3.85
- Technical
- Relative Strength Index (RSI)
- TNMG N/A
- MDXH 38.61
- Support Level
- TNMG N/A
- MDXH $1.80
- Resistance Level
- TNMG N/A
- MDXH $1.93
- Average True Range (ATR)
- TNMG 0.00
- MDXH 0.06
- MACD
- TNMG 0.00
- MDXH -0.01
- Stochastic Oscillator
- TNMG 0.00
- MDXH 41.67
About TNMG TNL MEDIAGENE
TNL Mediagene is a comprehensive media and data platform providing news and commentary on current events, business, technology, lifestyle and sports.
About MDXH MDxHealth SA
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA), and Europe.